Compare Citius Pharmaceuticals Inc (CTXR) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs TotalEnergies SE — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while TotalEnergies SE trades at $80.8 (market cap $180.15B). The key difference: TotalEnergies SE is far larger — about 12305.3× Citius Pharmaceuticals Inc's market cap, and TotalEnergies SE pays a 5.21% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | TTE | |
|---|---|---|
Market Cap | $14.64M | $180.15B |
Sector | Health | Energy |
52-Week High | $1.82 | $93.60 |
52-Week Low | $0.53 | $57.39 |
Enterprise Value | $10.86M | $214.29B |
Dividend Yield | — | 5.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
TotalEnergies (TTE) trades at $81.21, up 3.45% today, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 EPS of $2.45, beating expectations, but revenue has declined from $263.3B in 2022 to $182.3B in 2025. Valuation ratios are attractive with a P/E of 12.05 and EV/EBITDA of 4.93. Recent news highlights strategic moves in LNG and solar divestments to focus on larger renewable projects.
The outlook for TTE is supported by strong cash flow generation and a 'Buy' consensus from 57.6% of analysts, but risks include declining revenue trends, geopolitical exposure, and regulatory pressures. The stock offers value with solid profitability and shareholder returns via dividends, yet investors should weigh execution risks in its energy transition strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
